Zimmer Biomet (ZBH) Q3 revenue $2.063 billion vs $2.06 billion est.; adj. EPS $1.90 vs $1.90 est.
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Zimmer Biomet reported third-quarter 2026 net sales of $2.063 billion, up 3.1% year over year and 3.7% on a constant-currency basis, essentially matching the $2.06 billion consensus estimate. Adjusted diluted EPS came in at $1.90, in line with expectations and flat versus the prior-year period, while GAAP diluted EPS fell 13.8% to $1.00. Investors will watch the updated 2026 guidance details and the extended limited exclusive distribution and supply agreement with THINK Surgical as signals of momentum in the robotics portfolio.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR's report. It can get details wrong, so check the source.
Named in this story
Zimmer Biomet (ZBH), Ivan Tornos
A linked name opens that asset's sentiment page.